AAVantgarde Bio has closed a $141M (€122M) Series B financing round led by Schroders Capital, Atlas Venture, and Forbion. New investors included Amgen Ventures, Athos Capital, CDP Venture Capital, Columbia IMC, Neva SGR, Sixty Degree Capital, XGen Venture, and Willett Advisors. Existing investors Longwood Fund and Sofinnova Partners also participated.
AAVantgarde secures $141m Series B funding
Latest NewsAAVantgarde Bio has closed a $141M (€122M) Series B financing round led by Schroders Capital, Atlas Venture, and Forbion. New investors included Amgen Ventures, Athos Capital, CDP Venture Capital, Columbia IMC, Neva SGR, Sixty Degree Capital, XGen Venture, and Willett Advisors. Existing investors Longwood Fund and Sofinnova Partners also participated.
How T3 scaled faster in Basel’s biotech labs
slider, Sponsored PublicationsT3 Pharmaceuticals shows how a biotech can move from first experiments to a major international deal keeping pace – and roots – in the Basel Area. The team built, tested and scaled inside Switzerland Innovation Park Basel Area’s Main Campus. Flexible private labs, certified shared facilities and an on-site expert community cut friction at every step. The result: faster iteration, smarter use of capital and a clear path from seed to global relevance — all inside Europe’s densest life sciences cluster.
Novo and Pfizer in Metsera takeover battle
Latest NewsDanish Novo Nordisk A/S has made an unexpected takeover bid for US biotech Metsera, Inc. This challenges the already agreed acquisition by Pfizer Inc. Novo offers US$6.5bn in cash, plus up to US$2.5bn in milestone payments. The total potential value is around US$9bn. Pfizer previously offered US$4.9bn plus US$2.4bn in milestones.
Data-driven excellence: the cornerstone of clinical research
BackgroundEssential areas such as study planning, interpretation, regulatory guidance, and key study design decisions remain human responsibilities, although AI increasingly supports routine tasks. X-act gets involved after the preclinical phase supporting clients in all clinical research phases from Phase I to IV and beyond. Their service ranges from initial planning to final analysis, reporting, and regulatory submission. European Biotechnology spoke with Jasmin Atarodi, Managing Director of X-act Cologne Clinical Research GmbH, about the benefits of partnering with experienced data specialists.
NATO elevates biotech to defence priority
Latest NewsThe NATO is clearly priorising biotech to a defence priority with an annual budget of potentially up to €500m for biotech start-ups starting from 2026. At the opening of the first ever NATO Biotechnology Conference, NATO Secretary General Mark Rutte said: “Between last year and this year, we funded a total of 28 promising biotechnology companies through the Defence Innovation Accelerator for the North Atlantic (DIANA)”. Rutte indicated that DIANA’s budget could grow significantly in the medium term, potentially up to five-fold.
Solid tumours meet their match
BackgroundSolid tumours pose major obstacles for cell therapies, but German-American biotech T-knife is tackling them head-on. CEO Tom Soloway and CTO Elisa Kieback share how their “supercharged” TCR-Ts are engineered to overcome these challenges.
GSK licences siRNA COPD drug in US$745m biobucks deal
Latest NewsBritish GlaxoSmithKline plc (GSK) has entered a US$745m licensing agreement with Empirico Inc for EMP-012, a first-in-class siRNA candidate for COPD. EMP-012 targets the underserved non-type 2 inflammation market segment valued at US$600–700bn.
Novartis acquires Avidity Biosciences for US$12bn
Latest NewsIn a major bet on RNA medicine, Swiss Novartis AG announced to buy Avidity Biosciences Inc for US$12bn. Avidity’s Oligonucleotide Conjugate (AOC) platform allows Transferin receptor-targeted RNA delivery to muscle. With the acquisition Novartis secures access to three late-stage RNA drug candidates for muscular dystrophies.
GHO Capital expands healthcare reach with €2.5bn Fund IV close
Latest NewsGHO Capital has closed its fourth fund, GHO Capital IV LP, raising over €2.5bn (~US$2.9bn) to invest in global healthcare. The fund brings the firm’s total assets under management to around €9bn, making it Europe’s largest healthcare-focused private equity firm.
Hemab Therapeutics bags US$157m in Series C financing
Latest NewsHemab Therapeutics A/S has completed an oversubscribed US$157m Series C financing round led by Sofinnova Partners to accelarate and expand its pipeline in bleeding disorders and thrombosis treatments.